As filed with the Securities and Exchange Commission on November 23, 2011
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
84-1460811 |
|
(State or other jurisdiction of |
|
(I.R.S. Employer |
3200 Walnut Street Boulder, CO 80301
(Address of Principal Executive Offices)(Zip Code)
ARRAY BIOPHARMA INC. EMPLOYEE STOCK PURCHASE PLAN
(Full title of the plan)
Robert E. Conway
Chief Executive Officer
Array BioPharma Inc.
3200 Walnut Street
Boulder, Colorado 80301
(303) 381-6600
(Name, address and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one)
|
Large accelerated filer o |
Accelerated filer x |
|
Non-accelerated filer o |
Smaller Reporting Company o |
|
(do not check if a smaller reporting company) |
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
Proposed |
|
Proposed |
|
|
| |||
|
Title of each class of securities |
|
Amount to be |
|
maximum offering |
|
maximum aggregate |
|
Amount of |
| |||
|
to be registered |
|
registered(1) |
|
price per share (2) |
|
offering price (2) |
|
registration fee |
| |||
|
EMPLOYEE STOCK PURCHASE PLAN Common Stock, par value $.001 |
|
600,000 |
|
$ |
2.33 |
|
$ |
1,398,000 |
|
$ |
160 |
|
|
AMENDED AND RESTATED STOCK OPTION AND INCENTIVE PLAN Common Stock, par value $.001 |
|
5,258,337 |
|
$ |
2.33 |
|
$ |
12,257,926 |
|
$ |
1,405 |
|
(1) This Registration Statement shall also cover any additional shares of common stock which become issuable under the Employee Stock Purchase Plan and the Amended and Restated Stock Option and Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of the outstanding shares of Registrant’s common stock.
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act of 1933, as amended. The offering price per share and the aggregate offering price are based upon the average high and low prices of the Registrant’s common stock as reported on The Nasdaq Stock Market on November 21, 2011 of $2.33.
EXPLANATORY NOTE
Array BioPharma Inc. (the “Registrant”) filed with the Securities and Exchange Commission (the “Commission”) Registration Statements on Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), (i) on December 6, 2000 (Reg. No. 333-51348) covering the registration of 800,000 shares of the common stock of the Registrant authorized for grant under the Array BioPharma Inc. Employee Stock Purchase Plan (the “ESPP”) and the registration of 5,941,463 shares of the common stock of the Registrant authorized for grant under the Amended and Restated Array BioPharma Inc. Stock Option and Incentive Plan (the “Plan”), (ii) on November 4, 2002 (Reg. No. 333-100955) covering the registration of 400,000 shares of the common stock of the Registrant authorized for grant under the ESPP and the registration of 2,750,000 shares of the common stock of the Registrant authorized for grant under the Plan, (iii) on March 3, 2006 (Reg. No. 333-132205) covering the registration of 4,870,432 shares of the common stock of the Registrant authorized for grant under the Plan, (iv) on December 18, 2006 (Reg. No. 333-139450) covering the registration of 450,000 shares of the common stock of Registrant authorized for grant under the ESPP, (iv) on November 7, 2008 (Reg. No. 333-155219) covering the registration of 600,000 shares of the common stock of the Registrant authorized for grant under the ESPP, (v) on April 17, 2009 (Reg. No. 333-158624) covering the registration of 4,445,519 shares of the common stock of the Registrant’s authorized for grant under the Plan, (vi) on November 16, 2009 (Reg. No. 333-163138) covering the registration of 600,000 shares of the common stock of the Registrant authorized for grant under the ESPP, and (vii) on December 22, 2010 (Reg. No. 333-171361) covering the registration of 600,000 shares of the common stock of the Registrant authorized for grant under the ESPP and 2,822,787 shares of the common stock of the Registrant authorized for grant under the Plan. As permitted by Instruction E of Form S-8, the contents of Registration Statement Nos. 333-51348, 333-100955, 333-132205, 333-139450, 333-155219, 333-158624, 333-163138 and 333-171361 filed by the Registrant on Form S-8 on December 6, 2000, November 4, 2002, March 3, 2006, December 18, 2006, November 7, 2008, April 17, 2009, November 16, 2009 and December 22, 2010, respectively, are incorporated herein by reference.
On September 1, 2011, the Registrant’s Board of Directors approved an amendment to the ESPP increasing the number of shares of common stock available for issuance thereunder by 600,000 shares. The stockholders of the Registrant approved the amendment to the ESPP at the annual meeting of stockholders held on October 26, 2011. A description of the amendment to the ESPP is included in the Registrant’s definitive proxy statement on Schedule 14A dated September 15, 2011, with respect to the Registrant’s annual meeting of stockholders held on October 26, 2011. This registration statement registers the additional 600,000 shares of common stock authorized for issuance under the ESPP.
Pursuant to the provisions of the Plan, the number of shares authorized for grant under the Plan increases automatically based on a percentage of the number of shares of common stock of the registrant outstanding. On October 26, 2011, the Board of Directors approved resolutions acknowledging that there are 5,258,337 additional authorized shares available for issuance as awards under the Plan. This registration statement registers an additional 5,258,337 shares of common stock authorized for grant under the Plan pursuant to the terms of such provision.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) and are incorporated herein by reference:
· the Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011 filed with the Commission on August 12, 2011;
· the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011 from the Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on September 15, 2011;
· the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2011 and filed with the Commission on November 2, 2011, as amended on Form 10-Q/A filed with the Commission on November 3, 2011;
· the Registrant’s Current Reports on Form 8-K, filed with the Commission on July 13, 2011, August 9, 2011, August 17, 2011, September 8, 2011, September 30, 2011 and November 1, 2011; and
· the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A filed with the Commission on November 16, 2000, including any amendments or reports filed for the purpose of updating such description.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.
For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
See Exhibit Index.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on this 23rd day of November 2011.
|
|
|
ARRAY BIOPHARMA INC. | |
|
|
|
| |
|
|
|
By |
/s/ Robert E. Conway |
|
|
|
|
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert E. Conway, R. Michael Carruthers and John R. Moore, jointly and severally, each in his own capacity, his true and lawful attorneys-in-fact, with full power of substitution, for him and his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, with full power and authority to do so and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact of any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Robert E. Conway |
|
Chief Executive Officer and Director |
|
November 23, 2011 |
|
Robert E. Conway |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
/s/ Kyle A. Lefkoff |
|
Chairman of the Board of Directors |
|
November 23, 2011 |
|
Kyle A. Lefkoff |
|
|
|
|
|
|
|
|
|
|
|
/s/ R. Michael Carruthers |
|
Chief Financial Officer |
|
November 23, 2011 |
|
R. Michael Carruthers |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
|
|
/s/ Francis J. Bullock |
|
Director |
|
November 23, 2011 |
|
Francis J. Bullock, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Kevin Koch |
|
Director |
|
November 23, 2011 |
|
Kevin Koch, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ David L. Snitman |
|
Director |
|
November 23, 2011 |
|
David L. Snitman, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Gil Van Lunsen |
|
Director |
|
November 23, 2011 |
|
Gil Van Lunsen |
|
|
|
|
EXHIBIT INDEX
|
Exhibit |
|
|
|
Number |
|
Description of Exhibit |
|
4.1(1) |
|
Specimen certificate representing the common stock. |
|
|
|
|
|
4.2(2) |
|
Form of Warrant to purchase shares of the registrant’s Common Stock issued to Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield Partners, L.P., Deerfield International Limited |
|
|
|
|
|
4.3(3) |
|
Form of Amendment No. 1 to Warrant to purchase shares of the registrant’s Common Stock issued to Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield Partners, L.P., Deerfield International, Limited |
|
|
|
|
|
4.4(4) |
|
Registration Rights Agreement dated May 15, 2009 between the Registrant and Deerfield Private Design Fund, L.P. and Deerfield Private Design International, L.P. |
|
|
|
|
|
5.1 |
|
Opinion of Gross Hartman LLC with respect to the legality of the common stock registered hereby. |
|
|
|
|
|
23.1 |
|
Consent of KPMG LLP, Independent Registered Public Accounting Firm with respect to the Registrant. |
|
|
|
|
|
23.2 |
|
Consent of Gross Hartman LLC (contained in its opinion filed as Exhibit 5.1). |
|
|
|
|
|
24.1 |
|
Power of Attorney (included on the signature page to this Registration Statement). |
|
|
|
|
|
99.1(5) |
|
Amended and Restated Array BioPharma Inc. Employee Stock Purchase Plan. |
|
|
|
|
|
99.2(6) |
|
Amended and Restated Array BioPharma Inc. Stock Option and Incentive Plan. |
(1) Filed as an exhibit to the Registrant’s Registration Statement on Form S-1 (File No. 333-45922), as amended, and incorporated herein by reference.
(2) Filed as an exhibit to the Registrant’s Current Report on Form 8-K/A filed with the SEC on September 24, 2009 (File No. 001-16633).
(3) Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed with the SEC on May 2, 2011 (File No. 001-16633).
(4) Filed as an exhibit to the registrant’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2009 (File No. 001-16633).
(5) Filed as an appendix to the Registrant’s definitive proxy statement on Schedule 14A dated September 15, 2011, with respect to the annual meeting of stockholders held on October 26, 2011 (File No. 001-16633).
(6) Filed as an appendix to the Registrant’s definitive proxy statement on Schedule 14A dated September 26, 2008 with respect to the annual meeting of stockholders held on October 30, 2008 (File No. 001-16633).